Memorial Sloan Kettering Cancer Center - Pharmaceuticals & Healthcare - Deals and Alliances Profile
September 2018
81
About the Report
About the Report
Summary
Memorial Sloan Kettering Cancer Center (MSKCC) is a healthcare service provider that offers cancer treatment, cancer research and cancer education programs. The center conducts research in therapeutic areas of bone and marrow stem cell transplantation, cancer pathology, cancer therapeutics and drug development, cell biology, cell cycle regulation, cell death, cell signaling, immunology, genetics and genomics, molecular imaging and tumor growth. It provides diagnosis and treatment for cancer diseases such as adrenal tumors, AIDS-associated cancers, basal cell carcinoma, benign blood disorders, bladder cancer, bone cancer, brain tumors and breast cancer among others. The center also offers predoctoral and postdoctoral training. MSKCC is headquartered in New York, the US.
Memorial Sloan Kettering Cancer Center-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Memorial Sloan Kettering Cancer Center, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Memorial Sloan Kettering Cancer Center, Medical Devices Deals, 2012 to YTD 2018 11
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deal Details 16
Venture Financing 16
ORIC Pharma Raises USD50 Million in Series C Financing 16
Partnerships 18
Context Therapeutics Enters into Research Collaborations for Apristor 18
Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20
Bridge Medicines Enters into Agreement with Memorial Sloan Kettering Cancer Center 21
BlueRock Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 22
Telix Pharma Enters into Agreement with Memorial Sloan Kettering Cancer 23
Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 24
PathoQuest Enters into Agreement with Memorial Sloan Kettering 25
OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 26
Royal Philips and Memorial Sloan Kettering Cancer Center Enter into Research Agreement 27
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 28
Aprea Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 29
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 30
Multiple Myeloma Research Foundation Enters into Agreement with Memorial Sloan Kettering Cancer Center 31
Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 32
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 33
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 34
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 35
Cesca Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 36
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 37
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 38
Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 39
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 40
Licensing Agreements 41
Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering 41
Immune-Onc Therapeutics Enters into Licensing Agreement with Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center 42
Abpro Enters into Licensing Agreement with Memorial Sloan Kettering Cancer 43
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 44
Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 45
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 47
Gritstone Oncology Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 48
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 49
Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 50
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 51
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 53
Sellas Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center for Vaccine to Target WT1 for Cancer 55
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 56
Jounce Therapeutics Amends Licensing Agreement for JTX-2011 58
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 60
Memorial Sloan Kettering Cancer Center-Key Competitors 61
Memorial Sloan Kettering Cancer Center-Key Employees 62
Memorial Sloan Kettering Cancer Center-Locations And Subsidiaries 63
Head Office 63
Other Locations & Subsidiaries 63
Joint Venture 64
Recent Developments 65
Government and Public Interest 65
Jul 18, 2018: St. Baldrick's foundation announces USD 19.1 million in grants to fund lifesaving childhood cancer research 65
Jun 26, 2018: Pancreatic Cancer Action Network Funds Innovative Scientists through Research Grants Program 66
May 02, 2018: St. Baldrick's Foundation Supports Innovative Childhood Cancer Research Through One-of-a-Kind Grant 67
Mar 21, 2018: Leukemia Patient's Legacy Helps Drive Innovative Cancer Clinical Trial 68
Feb 02, 2018: BCRF Announces Expansion of the Drug Research Collaborative 70
Feb 01, 2018: Fusions in Solid Tumours 71
Dec 14, 2017: Cancer Immunotherapy May Work Better in Patients with Specific Genes 72
Nov 14, 2017: St. Baldrick's Foundation Announces USD 2.2 Million in Grants to Give More Kids Access to Clinical Trials 73
Nov 02, 2017: Lung Cancer Research Foundation Awards USD 1.6 Million in Research Grants 74
Nov 02, 2017: New System for Treating Colorectal Cancer Can Lead to Complete Cure 76
Nov 01, 2017: CVS Health Foundation Awards USD 1 Million Dollars in Grants to Eight Cancer Centers to Increase Smoking Cessation Resources in the Oncology Setting 77
Sep 21, 2017: Grant funds chemotherapy-free breast cancer therapy research 78
Jun 01, 2017: The T.J. Martell Foundation Announces New Appointments to Board of Directors and USD 1.3M in Cancer Research Grants 79
Other Significant Developments 80
May 14, 2018: New Tool Helps People with Leukemia Better Understand Their Treatment Options 80
Appendix 81
Methodology 81
About GlobalData 81
Contact Us 81
Disclaimer 81
List of Figure
List of Figures
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Memorial Sloan Kettering Cancer Center, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Memorial Sloan Kettering Cancer Center, Deals By Therapy Area, 2012 to YTD 2018 10
Memorial Sloan Kettering Cancer Center, Medical Devices Deals, 2012 to YTD 2018 11
Memorial Sloan Kettering Cancer Center, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
ORIC Pharma Raises USD50 Million in Series C Financing 16
Context Therapeutics Enters into Research Collaborations for Apristor 18
Immunomedics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 20
Bridge Medicines Enters into Agreement with Memorial Sloan Kettering Cancer Center 21
BlueRock Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 22
Telix Pharma Enters into Agreement with Memorial Sloan Kettering Cancer 23
Daiichi Sankyo and Puma Biotech Enter into Research Agreement with Memorial Sloan Kettering Cancer Center 24
PathoQuest Enters into Agreement with Memorial Sloan Kettering 25
OSE Immunotherapeutics Enters into Partnership with Memorial Sloan Kettering Cancer Center 26
Royal Philips and Memorial Sloan Kettering Cancer Center Enter into Research Agreement 27
MabVax Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 28
Aprea Therapeutics Enters into Research Partnership with Memorial Sloan Kettering Cancer Center 29
Avacta Group Enters into Agreement with Memorial Sloan Kettering Cancer Center 30
Multiple Myeloma Research Foundation Enters into Agreement with Memorial Sloan Kettering Cancer Center 31
Seres Therapeutics Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 32
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 33
Genocea Biosciences Enters into Agreement with Memorial Sloan Kettering Cancer Center 34
Advaxis Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 35
Cesca Therapeutics Enters into Agreement with Memorial Sloan Kettering Cancer Center 36
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 37
MabVax Therapeutics Enters into Co-development Agreement with Memorial Sloan Kettering Cancer Center 38
Sutro Biopharma Enters Into Co-Development Agreement With Memorial Sloan-Kettering Cancer Center 39
Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute Form Joint Venture 40
Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering 41
Immune-Onc Therapeutics Enters into Licensing Agreement with Albert Einstein College of Medicine and Memorial Sloan Kettering Cancer Center 42
Abpro Enters into Licensing Agreement with Memorial Sloan Kettering Cancer 43
Lin Bioscience Enters into Licensing Agreement with Columbia University and Memorial Sloan Kettering Cancer Center 44
Fate Therapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 45
Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 47
Gritstone Oncology Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 48
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 49
Y-mAbs Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 50
Atara Biotherapeutics Expands Licensing Agreement with Memorial Sloan Kettering Cancer 51
Aduro BioTech Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center, Rockefeller University, Rutgers and University of Bonn 53
Sellas Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center for Vaccine to Target WT1 for Cancer 55
Eureka Therapeutics And Memorial Sloan-Kettering Cancer Center Enter Into Licensing Agreement With Novartis 56
Jounce Therapeutics Amends Licensing Agreement for JTX-2011 58
Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 60
Memorial Sloan Kettering Cancer Center, Key Competitors 61
Memorial Sloan Kettering Cancer Center, Key Employees 62
Memorial Sloan Kettering Cancer Center, Other Locations 63
Memorial Sloan Kettering Cancer Center, Subsidiaries 63
Memorial Sloan Kettering Cancer Center, Joint Venture 64
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.